COLORADO SPRINGS, Colo.,
July 18, 2014 /PRNewswire/
-- Cannabis Science, Inc. (OTC:CBIS), a U.S. Company
specializing in cannabis formulation-based drug development and
related consulting bring attention to more evidence on the investor
appetite to invest in quality companies.
This week, the Wall Street Journal wrote a commentary piece
entitled "Pot Industry Puts a Tie On" where Chief Financial Officer
of Cannabis Science, Inc. Robert
Kane provides his economic insight on the industry and
explains growth challenges this sector is going through as they
mature into a larger market. A version of the entire article
is available for viewing at the link below:
http://mobile.blogs.wsj.com/cfo/2014/07/15/pot-industry-puts-on-a-tie/?mg=blogs-wsj
"Thank you to John Kester for
bringing attention to this industry. To me this article is more
evidence of the maturing investor appetite for the cannabis
industry, seeking quality and investing in companies with strong
executive management teams and quality advisory boards. There
are challenges but I am honored to be a part of the team that
overcomes every one of these challenges." Stated Robert Kane, CFO
Cannabis Science.
About Cannabis Science, Inc.
Cannabis Science, Inc.,
takes advantage of its unique understanding of metabolic processes
to provide novel treatment approaches to a number of illnesses for
which current treatments and understanding remain unsatisfactory.
Cannabinoids have an extensive history dating back thousands of
years, and currently, there are a growing number of peer-reviewed
scientific publications that document the underlying biochemical
pathways that cannabinoids modulate. The Company works with leading
experts in drug development, medicinal characterization, and
clinical research to develop, produce, and commercialize novel
therapeutic approaches for the treatment for illnesses caused by
infections as well as for age-related illness. Our initial focus is
on skin cancers and neurological conditions.
Forward-Looking Statements
This Press Release includes
forward-looking statements within the meaning of Section 27A of the
Securities Act of 1933 and Section 21E of the Securities Act of
1934. A statement containing words such as "anticipate," "seek,"
intend," "believe," "estimate," "expect," "project," "plan," or
similar phrases may be deemed "forward-looking statements" within
the meaning of the Private Securities Litigation Reform Act of
1995. Some or all of the events or results anticipated by these
forward-looking statements may not occur. Factors that could cause
or contribute to such differences include the future U.S. and
global economies, the impact of competition, and the Company's
reliance on existing regulations regarding the use and development
of cannabis-based drugs. Cannabis Science, Inc., does not undertake
any duty nor does it intend to update the results of these
forward-looking statements.
Cannabis Science, Inc.
Dr. Dorothy Bray, CEO &
Director
www.cannabisscience.com
dorothy.bray@cannabisscience.com
info@cannabisscience.com
Tel: 1.888.777.0658
Investment Inquiries
Robert Kane, CFO & Director
robert.kane@cannabisscience.com
Tel: 1.561.420.4824
Cannabis Science, Inc.
Raymond C. Dabney, Management
Consultant, Co-Founder
raymond@cannabisscience.com
Tel: 1.310.650.3788
SOURCE Cannabis Science, Inc.